Klin Onkol 2001; 14(4): 114-119.
Abstract: PSA is currently the most important clinical tumor marker of prostate cancer. Authors focus on molecular forms of PSA and their characteristics, factors influencing serum concentration of PSA, problems of screening and especially possibilities of utilization of PSA for detection of prostate cancer. The main problem in the detection of prostate cancer is a low specificity of PSA in the range of 4-10 ng/ml, so called “diagnostic gray zone”, in which prostate cancer occurs in only 25% of patients. Methods enabling to improve sensitivity and/or specificity of PSA (free PSA, PSA density, PSA density of the transition zone, age-specific PSA, PSA velocity, PSA doubling time, RT-PCR technique) are evaluated
